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ABSTRACT
Glioblastoma multiforme (GBM) is the most malignant brain tumor, showing high 
resistance to standard therapeutic approaches that combine surgery, radiotherapy, 
and chemotherapy. As opposed to healthy tissues, EphA2 has been found highly 
expressed in specimens of glioblastoma, and increased expression of EphA2 has 
been shown to correlate with poor survival rates. Accordingly, agents blocking Eph 
receptor activity could represent a new therapeutic approach. Herein, we demonstrate 
that UniPR1331, a pan Eph receptor antagonist, possesses significant in vivo anti-
angiogenic and anti-vasculogenic properties which lead to a significant anti-tumor 
activity in xenograft and orthotopic models of GBM. UniPR1331 halved the final 
volume of tumors when tested in xenografts (p<0.01) and enhanced the disease-free 
survival of treated animals in the orthotopic models of GBM both by using U87MG cells 
(40 vs 24 days of control, p<0.05) or TPC8 cells (52 vs 16 days, p<0.01). Further, 
the association of UniPR1331 with the anti-VEGF antibody Bevacizumab significantly 
increased the efficacy of both monotherapies in all tested models. Overall, our data 
promote UniPR1331 as a novel tool for tackling GBM.
INTRODUCTION
Glioblastoma multiforme (GBM), the most 
malignant brain tumor, shows high resistance to standard 
treatments consisting of different approaches that include 
surgery, radiotherapy and chemotherapy [1]. GBM 
shows a median overall survival (OS) of 14.6 months for 
newly diagnosed cases [2]. Failure of standard chemo/
radiotherapy is attributed to multiple factors, such as 
microenvironment protection, de novo and/or acquired 
tumor resistance, limitations in drug delivery, increased 
angiogenesis and/or vasculogenic mimicry (VM), and 
presence of glioma stem cells (GSCs) [3].
Eph receptors are the largest subfamily of RTKs, 
with 16 known members. They are divided into “A” and 
“B” sub-classes, and they are activated by membrane 
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proteins known as ephrins (Eph family receptor interacting 
proteins) [4]. These receptors are activated upon binding 
with their cognate ephrin ligands, which induce receptor 
clustering, followed by internalization and degradation. 
Eph receptors and their corresponding ligands play critical 
functions during early embryogenesis and development 
[5]. Recently, few Eph receptors along with their ligands 
have been implicated in the insurgence of several 
malignancies including GBM [6]. Indeed, the expression 
of EphA and EphB receptors in GBM has been correlated 
with poor prognosis [7]. Recent findings have proposed 
that EphA2 and EphA3 not only sustain the survival 
of GBM primary lines but also promote the renewal of 
tumor-propagating cells with stem-like characteristics 
(TPC). In these cells, both the receptors maintain an 
undifferentiated, self-renewing tumor population limiting 
MAPK signaling. In fact sustained ERK1/2 signaling 
leads to differentiation and reduces the proliferation and 
tumorsphere-forming capacity of GBM cells, whilst a 
transient ERK1/2 signaling keeps GBM cells in a stem-
like state [8]. Additionally, Eph/ephrin signaling has been 
suggested to be a controlling factor in vasculomimicry 
(VM) [9] and tumor angiogenesis [10] where EphA2 
emerged as a pivotal driver. Moreover, it has been recently 
demonstrated that Eph receptors activation through 
ephrin-B2 has a prominent role in perivascular invasion 
and in vascular co-option on GSCs [11].
These premises prompted several research 
groups to search for new antitumor strategies based 
on the exploitation of the Eph/ephrin system. These 
drug discovery expeditions allowed to identify ATP-
mimicking agents targeting Eph kinase domain or other 
pharmacological tools including peptides, proteins, 
antibodies and small molecules, targeting Eph/ephrin 
binding interface [12]. We actively contributed to this 
field discovering and optimizing several protein-protein 
interaction (PPI) inhibitors capable of preventing Eph-
ephrin interaction [13–15] and including the first orally 
bioavailable Eph antagonist UniPR1331 [16]. UniPR1331 
targets the ectodomain of EphA2 with a steady-state 
affinity constant (KD) of 3.4 μM, dose-dependently 
blocked EphA2 phosphorylation in human umbilical 
Figure 1: Effect of UniPR1331 on angiogenesis. (A) representative pictures at 10x magnification. (B) Quantification of HBMVE 
cells tube formation as branching index analysis. (C) in vivo angiogenic assay. CAMs were implanted with alginate plugs adsorbed with 
or without VEGF and the compound. After 72 h the angiogenic response was scored. Representative photographs of CAMs incubated 
with/without VEGF in the absence or in the presence of 10μM UniPR1331. (D) Count of the number of vessels/egg in presence of VEGF 
(positive control) and after inhibition with 10 μM UniPR1331. Data are the mean ± SEM of 3 independent experiments ***: p<0.001, one-
way ANOVA followed by Dunnett’s post-hoc test.
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vein endothelial cells (HUVEC) and reduced their ability 
to form blood vessels with an IC50 of 2.9 μM [16]. The 
compound inhibited the interaction of ephrin-A1 with all 
the EphA kinases and ephrin-B1 with all the EphB kinases 
[16] acting as a pan-Eph/ephrin inhibitor. Considering the 
primary role of the Eph/ephrin system in GBM and the 
availability of a compound able to specifically target the 
Eph receptors, we examined whether UniPR1331 was 
capable of inhibiting GBM growth in vivo. Since anti-
angiogenic compounds targeting endothelial cells have 
been considered for treatment of recurrent GBM [17] 
but their clinical benefit was unsatisfactory [18, 19], 
we decided to test the association of UniPR1331 with 
Bevacizumab, a specific and selective inhibitor of VEGF-
VEGFR interaction.
RESULTS
UniPR1331 inhibits in vitro and in vivo 
angiogenesis
UniPR1331 dose-dependently decreased in 
vitro tube formation of HUVE cells [16] and, here, 
we demonstrated that the compound reduced the 
phosphorylation of EphA2 receptor without modifying 
EphA2 expression after 16 hours (Supplementary Figure 
1 and Supplementary Figure 2). The compound was 
tested on human brain microvascular endothelial cells 
(HBMVEC) and in the chick chorioallantoic membrane 
(CAM) assay, in vivo, in presence of soluble factors 
stimulating the proliferation of primitive vessels and 
their differentiation to a functional arteriovenous system. 
The compound blocked the tube formation of HBMVEC 
in a concentration-dependent manner, with an IC50 of 
3.9μM (Figure 1A and 1B), consistent with its inhibitory 
potency of 2.9 μM on EphA2-ephrin-A1 and EphB4-
ephrin-B1 displacement assays [16]. Anti-angiogenic 
activity of UniPR1331 was confirmed in vivo in the CAM 
assay, where it dramatically inhibited vessel formation 
induced by VEGF165 (Figure 1C, 1D), without a direct 
action on VEGFR2 as UniPR1331 did not interfere with 
the kinase activity of VEGFR2 (Supplementary Table 
1). Beside the effect on vasculature cells, UniPR1331 
inhibited ephrin-A1 induced EphA2 phosphorylation 
decreasing EphA2 expression after 24 hours on U87MG 
cells (Supplementary Figure 1, Supplementary Figure 2), 
without interfering with the enzymatic activity of EphA2 
(Supplementary Table 1).
UniPR1331 selectively targets Eph/ephrin 
system
The specificity of UniPR1331 for the Eph-ephrin 
system was evaluated by testing the compound on several 
targets promoting tumor angiogenesis (ICAM-1, PDGFR, 
and FGFR) and proliferation (TGF-β, EGFR). Since GBM 
growth is also regulated by the LXR-cholesterol axis [20], 
we asked whether UniPR1331 may display any effect 
on this system. When tested up to 10 μM, UniPR1331 
did not modify the activity of any of these receptors 
(Supplementary Table 1). Finally, as the structure of 
UniPR1331 suggested connections with compounds 
targeting receptors or enzyme involved in metabolism of 
glucose, we tested it on TGR5, PPAR-γ, GLP-1 and DPP-
IV (Supplementary Table 1). Again, UniPR1331 failed to 
affect the activity of these targets up to 10 μM.
UniPR1331 inhibits GBM growth and extends 
the time to progression in vivo compared to the 
control: subcutaneous xenograft model
UniPR1331 was tested in vivo for its ability 
to inhibit the tumorigenic activity of U87MG cells 
following oral administration in nude mice at 30 mg/
kg os (five days a week) and the activity was compared 
with the standard anti-angiogenic drug Bevacizumab 
(4 mg/kg iv every 4 days) which inhibits VEGF 
receptors activation by binding to VEGF. To this 
aim, U87MG glioblastoma cells were subcutaneously 
injected and animals were randomly distributed in 
vehicle-, UniPR1331- or Bevacizumab-treated groups 
when tumors approximately reached 200mm3 volume. 
UniPR1331 exerted a significant inhibitory effect on the 
growth of human tumor grafts, compared to the control 
and showed an activity comparable to Bevacizumab 
(Figure 2). The treatment with UniPR1331 significantly 
increased the time to progression (TTP) from 9.9 to 15.8 
days (Figure 2A, 2D) and halved the final tumor weight 
from 709±145 mg to 327±72 mg (Figure 2B, 2C, 2D). 
Moreover, the proliferation index Ki67 was reduced from 
44.6% to 14.5%, the apoptotic cells increased from <2% 
to 8.5% and the vessel count dramatically decreased from 
23.2 to 5.5. Similar results on TTP, tumor weight, and 
vessel count were obtained with Bevacizumab, whilst 
no effect was detected on apoptosis suggesting that, as 
opposed to Bevacizumab, UniPR1331 does not solely 
act as an antiangiogenic drug (Figure 2). It is worth 
note that toxicological studies showed that the treatment 
with UniPR1331 did not result in major adverse effects 
with the exception of a low platelet count of 207x103/
μl and minor adaptive changes in liver and kidney 
(Supplementary Table 2).
Immunohistochemical evaluation of EphA2 (Figure 
2E, panels a, b) showed that this receptor stained U87MG 
tumor cells and endothelial cells (panel b) in about 40% 
of the tumor area (as shown in the low magnification 
100x picture, panel a with a SI score of 6). Treatment 
with UniPR1331 reduced EphA2 immunostaining 
(Figure 2E panels c, d) to about 20% of tumor area (SI 
score=4). Further analyses showed that EphA2 is basally 
phosphorylated (on Tyrosine) in about 30% of tumor areas 
with a strong immunostaining (Figure 2E panel e, f with 
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a SI=6). Treatment with UniPR1331 significantly reduced 
the immunostaining for p-Tyr-EphA2 (Figure 2E panels 
g, h, with a SI=2). A moderated staining was yet present 
in endothelial vessels (panel h) but not in vasculogenic 
mimetic vessels.
Combination between Bevacizumab and 
UniPR1331 overcomes the limits of anti-VEGF 
based treatment in GBM xenografts
We next tested the association of UniPR1331 
(30 mg/kg os qd) and Bevacizumab (4 mg/kg iv every 
4 days) on mice xenografts to assess its antitumor 
effect in vivo with U87MG and U251MG cells. In our 
experimental conditions, UniPR1331 significantly 
increased the efficacy of Bevacizumab, further reducing 
tumor growth. For instance, U251MG untreated tumors 
reached a final weight of 839 mg, whereas xenograft 
treated with UniPR1331 plus Bevacizumab reached a 
final weight of 157 mg vs 311 mg of UniPR1331 alone 
and 345 mg of Bevacizumab monotherapy. Association 
of UniPR1331 with Bevacizumab reduced tumor weights 
of 75% and 81% for U87MG and U251MG cells, 
respectively. The shrinkage of the tumor mass induced 
by oral administration of UniPR1331 in combination 
with Bevacizumab, when compared to control, resulted 
in a significant increase of the time-to-progression (TTP) 
of about 128% and 106% with U87MG and U251MG, 
respectively (Figure 3 and Supplementary Table 3–6). 
The association of UniPR1331 with Bevacizumab led to 
a dramatic increase of apoptotic index, a major decrease 
of ki67 and a further reduction of vessel count when 
compared with monotherapy alone, both with U87MG 
and U251MG grafts, suggesting the interference with 
multiple cancer pathways (Supplementary Table 3 and 
Supplementary Table 5).
Periodic Acid-Schiff (PAS) staining on xenograft 
histological specimens showed that angiogenesis and 
vasculogenic mimicry are equally distributed in untreated 
U87MG xenografts (Figure 4A panels a, b). Histological 
slides from Bevacizumab treated animals, showed a 
significant reduction of vessel number (Figure 4A, panel 
c) along with a switch from angiogenesis to vasculogenic 
mimicry starting from single medium-sized vessels. In 
Figure 4A (panel c), 4 medium-sized vessels are reported 
and we focused our attention on the largest ones. In the left 
one (panel d), the endothelial cells (red arrows) delimitate 
nearly the majority of the vascular wall. In a very little 
portion of it a loss of the endothelial cells continuity 
was observed (blue arrow) with two tumor cells oriented 
towards the lumen of the vessel. This phenomenon was 
more evident in the right vessel where about 50% of the 
vascular wall was without endothelium and composed 
by forming a palisade-like structure (Figure 4A, panel 
Figure 2: UniPR1331 blocks in vivo U87MG growth. CD1 nude mice were subcutaneously injected with U87MG tumor cells and 
orally treated with 30 mg/kg UniPR1331, five days a week for five weeks. Tumor growth was assessed two times a week by measuring 
tumor diameters with a Vernier caliper. Bevacizumab (4 mg/kg iv every 4 days) was used as reference compound. (A) Kaplan-Meier curves 
generated for the comparisons of Bevacizumab, UniPR1331 and ctr. (B) Comparisons amongst treatments in terms of tumor weight, (C) 
Pictures of xenografted tumors. (D) Table reporting multiple parameters of the experiment. (E) Immunostaining performed on U87MG 
xenograft tissues collected from Vehicle-treated and UniPR1331-treated animals on total EphA2 and phospho-tyr-EphA2 expression *, ** 
p<0,05 or p<0.01 vs controls #, ## p<0,05 or p<0.01 UniPR1331 vs Bevacizumab, n=10.
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e). In this portion of the vessel, tumor cell layers were 
placed parallel to each other to give hardness to the 
vascular structure. The structure of the entire vessel 
was straightened by a dense PAS-positive connective 
matrix (black arrows). In the “vasculo-mimetic” region 
of the wall, a series of small vascular lacunae (micro-
capillaries, green arrows) were also present. The number 
of these structures is considerably higher in this PAS 
positive-enclosed area (about 20) compared to those 
formed in the “angiogenic” portion of the vessel (about 
7). Altogether, this analysis confirmed that Bevacizumab 
caused endothelial cell death but at the same time induced 
vasculogenic mimicry with several tumor cells engaged in 
the formation of vessel walls.
Administration of UniPR1331 resulted in a sensitive 
reduction of medium/large-sized vessels as well as of 
vascular lacunae. In these tissues, vascular lacunae are 
distribute in portions rich in PAS-positive regions (Figure 
4A, panels f, g). This condition was increased when 
UniPR1331 was co-administered with Bevacizumab 
(Figure 4A, panels h, i) as this association abolished the 
Bevacizumab-induced vasculomimicry. In Figure 4A 
(panels f, g) wide non-vascularized areas were found in 
UniPR1331-treated tumors and they were significantly 
increased when Bevacizumab and UniPR1331 were 
combined (panels h, i). Altogether, this data suggests a 
possible fibrotic reaction. For this reason the trichromic 
staining was performed (Figure 4B). Wide areas rich in 
Figure 3: Combination between UniPR1331 and bevacizumab in GBM grafts. CD1 nude mice were subcutaneously injected 
with either U87MG or U251MG tumor cells and treated with 30 mg/kg UniPR1331 os 5 days a week, 4 mg/kg Bevacizumab iv every 4 days 
or their combination for 30 days. Tumor growth was assessed two times a week by measuring tumor diameters with a Vernier caliper. (A) 
Comparisons amongst treatments in terms of tumor weight in U87MG grafts. (B) Kaplan-Meier curves were generated for the comparisons 
of control (ctr)- Bevacizumab- UniPR1331- and combination of Bevacizumab plus UniPR1331 in experimentation with U87MG cells. (C) 
Comparisons amongst treatments in terms of tumor weight in U251 grafts. (D) Kaplan-Meier curves were generated for the comparisons of 
control (ctr)- Bevacizumab- UniPR1331- and combination of Bevacizumab plus UniPR1331 in experimentation with U251MG cells. n=10.
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collagen fibers (stained in blue) indicate the presence of 
massive fibrosis (Figure 4B). In particular collagen fibers 
were dispersed in the parenchyma of untreated tumors 
(panels a and b) surrounding the vasculo-mimetic vessels 
in Bevacizumab treated specimens (panel c and d, blue 
arrows) and areas rich in vascular lacunae in UniPR1331 
treated tumors (panel e and f). In addition, in UniPR1331 
treated tumors, Masson Trichrome staining highlighted 
the presence of yellow/orange deposits probably as blood 
clots following venous thrombi (black arrows).
Orthotopic intracranial model with U87MG cells 
and pharmacokinetic
Before performing in vivo experiments using 
orthotopic cancer models with luciferase-expressing 
cells, we assessed the ability of UniPR1331 to access 
central nervous system (CNS) in healthy mice. The 
compound was administered 30 mg/kg os and it reached 
a maximal plasma concentration (Cmax) of 850 nM after 
30 minutes (tmax). Measurements by HPLC/MS of brain 
homogenates at selected time points (15’, 30’, 1h, 4h) 
after oral administration of UniPR1331 confirmed that 
the compound crosses the brain-blood barrier reaching a 
Cmax of nearly 100 nM at 30 minutes, with a plasma/brain 
concentration ratio close to 8, consistent with literature 
data [21] for compounds with similar lipophilicity 
(Supplementary Figure 3). Treatment with UniPR1331 
(DFS= 40.0 ± 16.8 days) or Bevacizumab (DFS = 28.5 ± 
5.8 days) for 30 days, significantly increased the disease-
free survival (DFS) period when compared to control (24.0 
± 5.2 days). A dramatic improvement of DFS was observed 
when UniPR1331 was administered in combination with 
Bevacizumab (DFS = 88.00 ± 27.5 days) Figure 5A, 5B. 
Analysis of the Kaplan-Meier curves indicated that the 
combination between UniPR1331 and Bevacizumab was 
significantly more effective than the treatment with both 
drugs taken individually (Figure 5E). Similar results were 
Figure 4: In vivo VM and angiogenesis from U87MG tumors. (A) Periodic Acid-Schiff (PAS) staining: glycols are oxidized 
to aldehydes with subsequent formation of pararosaniline adducts which are stained in pink/red (black arrows). PAS stains the basal 
membrane underlying the vascular endothelium and delimits vasculo-mimetic structure. Subpanels a, b (vehicle treated animals) show main 
and detailed framework with endothelial cells (red arrows) delimiting a central small-sized blood capillary. Small vasculo-mimetic micro-
capillaries (green arrows) are distributed uniformly in the tumor parenchyma. Subpanels c-e show PAS staining in Bevacizumab treated 
animals in which we have reduction of vessel number (subpanel c) and a switch from angiogenesis to vasculogenic mimicry starting from 
single medium-sized vessels (subpanel e blue arrows). We analyzed the two largest vessels in detail (subpanels d, e). Subpanels f, g: PAS 
staining in UniPR1331-treated animals showing a significant reduction in the number of medium/large-sized vessels as well as of vascular 
lacunae. Subpanels h, i: The reduced vascularization of the tissues was caused by UniPR1331 alone or co-administered with Bevacizumab. 
(B) Trichromic staining performed in Vehicle (subpanels a, b) Bevacizumab (subpanels c, d), UniPR1331 (subpanels e, f) and combination 
Bevacizumab plus UniPR1331 (subpanels g, h). Tumor areas rich in collagen fibers (stained in blue) indicating massive fibrosis colonized 
and eventually replaced vascular parenchyma of U87MG xenografts mainly in the combination treatment. In addition, in UniPR1331 
treated tumors, Masson Trichrome staining highlighted the presence of deposits yellow/orange probably as blood clots following venous 
thrombi (black arrows).
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obtained considering the overall survival: UniPR1331 
(OS=67.7 ± 7.8 days) and Bevacizumab (OS=59.8 ± 
6.2 days) significantly increased the OS when compared 
to control (OS=42.9 ± 2.7 days, p<0.05). A further 
improvement in the OS was observed when UniPR1331 
was combined with Bevacizumab (OS=113.00 ± 20.6 
days) (Figure 5C, 5D, 5E). These results suggest that the 
combination of UniPR1331 with Bevacizumab showed 
a cumulative effect on DFS and OS in differentiated 
U87MG cell model.
Orthotopic intracranial model with tumor-
propagating cells
Since EphA2, EphA3 and ephrin-B2 were described 
to regulate tumor-propagating cell self-renewal [8, 11, 
22], luciferase-transfected glioma stem cells (TPC8 
cell line) were injected into mouse brains. In these 
conditions, 30 days treatment with UniPR1331 (52.0 ± 
10.2 days) and Bevacizumab (DFS=44.0 ± 10.0 days) 
significantly (p<0.005) increased the DFS period when 
compared to control (16.0 ± 1.4 days). Kaplan-Meier 
curves showed no significant differences amongst single 
monotherapies (Figure 6A, 6B, 6E) while the association 
between UniPR1331 and Bevacizumab (DFS=92.5 ± 
22.2 days) displayed higher efficacy than treatments 
with both drugs taken individually. The increased lapse 
of tumor appearance was associated with a significant 
increase in median OS (Figure 6C-6D) of treated animals. 
The analysis of Kaplan-Meier curves indicates that 
Bevacizumab (OS=82.5 ± 3.6 days) and UniPR1331 
(101.5 ± 16.5 days) were effective in the increase of 
OS of TPC8 bearing animals. UniPR1331 increased 
the efficacy of Bevacizumab both in terms of mean OS 
(145.0 ± 15.8 days, p<0.01) and in term of reduction of 
mice in progression (HR=3.34, p<0.01). This combination 
resulted also significantly more effective than UniPR1331 
administered alone (HR=2.44, p<0.05 for DFS and 
HR=2.27, p<0.05 for OS) (Figure 6E).
Effect of UniPR1331 on miRNA involved in 
blood vessel formation
We finally set to test whether UniPR1331 and Eph/
ephrin targeting could interfere with protein expression of 
TPC8 cells. MiRNAs are small, non-coding RNAs that 
Figure 5: Combination between bevacizumab and UniPR1331 in U87MG orthotopic brain model. CD1 nude mice 
were intra brain injected with luciferase transfected U87MG cells and treated with 30 mg/kg UniPR1331 os 5 days a week, 4 mg/kg 
Bevacizumab iv every 4 days or their combination. (A) Comparison amongst treatments in terms of tumor appearance or disease free 
survival (DFS). (B) Kaplan-Meier curves were generated for the comparisons of control (vehicle)- Bevacizumab- UniPR1331- and 
combination of Bevacizumab plus UniPR1331 in terms of disease free survival. (C) Comparisons amongst treatments in terms of overall 
survival. (D) Kaplan-Meier curves were generated for the comparisons of control (vehicle)- Bevacizumab- UniPR1331- and combination 
of Bevacizumab plus UniPR1331 in terms of overall survival. (E) Statistical analysis: comparison of Kaplan Meier curves for UniPR1331 
alone or in combination with Bevacizumab. n=10.
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mediate post-transcriptional gene silencing. Since the 
recurrence in a resected and treated GBM is associated to 
cancer stem cell recruitment and growth, global miRNAs 
profile was assessed in TPC8 cells line following exposure 
to 10 μM UniPR1331 or DMSO 1% for 24 hr. A total of 
184 mature miRNAs, including 35 UniPR1331-induced 
and 149 UniPR1331-reduced miRNAs, significantly 
(p<0.05) distinguished treated cells from those untreated. 
Twenty-seven miRNAs exhibited a significant >2-fold 
UniPR1331-induced-up-regulation (RQ>2) and 70 
miRNAs showed <2-fold down-regulation (Figure 7A). 
The most highly expressed UniPR1331-induced miRNAs 
(RQ> 20) were hsa-miR-616-3p and hsa-miR-15a-3p 
whereas the most UniPR1331-reduced miRNAs (RQ < 
0.02) were hsa-miR-593-3p, hsa-miR-144-5p, hsa-miR-
501-3p, hsa-miR-326 and hsa-miR-199a-3p. On the basis 
of the Validate MiRWalk Module bioinformatics tool, used 
to identify the UniPR1331-deregulated miRNAs (targeting 
genes that have been proved experimentally), we selected 
12 over-expressed and 8 down-expressed miRNAs able to 
silence genes involved in the angiogenesis (Figure 7B and 
7C). Furthermore, we identify 21 UniPR1331-induced and 
35 UniPR1331-reduced miRNAs targeting glioblastoma-
related genes (DOID:3068 ontology) (Supplementary 
Tables 7 and 8), with 11 over-expressed and 8 down-
expressed all influencing glioblastoma and promoting 
angiogenesis inhibition (Figure 7D and 7E). The 
prediction analysis revealed that 27 UniPR1331-induced 
miRNAs were significantly enriched for their binding sites 
within the genes associated with angiogenesis activation 
(gene ontology GO:0045766) and 38 UniPR1331-reduced 
miRNAs targeted genes associated with angiogenesis 
inhibition (gene ontology GO:0016525) (data not shown). 
According to MiRWalk prediction algorithms, 7 over-
expressed and 19 down-expressed (Supplementary Table 
9) miRNAs could significantly (p <0.01) acted to reduce 
angiogenesis process in UniPR1331-treated TPC8 cells. 
Some miRNA may be associated to VM.
DISCUSSION
The overexpression of EphA2 in GBM tissues 
promotes glioma cell migration and invasion [23–26], 
while its activation concurs to the renewal of cancer stem 
Figure 6: Combination between bevacizumab and UniPR1331 in TPC8 orthotopic brain model. CD1 nude mice were 
intra brain injected with luciferase transfected TPC8 cells and treated with 30 mg/kg UniPR1331 os 5 days a week, 4 mg/kg Bevacizumab 
iv every 4 days or their combination for 30 days. Tumor growth was assessed two times a week by measuring tumor diameters with a 
Vernier caliper. (A) Comparisons amongst treatments in terms of disease free survival (DFS). (B) Kaplan-Meier curves were generated for 
the comparisons of control (ctr)- Bevacizumab- UniPR1331- and combination of Bevacizumab plus UniPR1331 in terms of disease free 
survival. (C) Comparisons amongst treatments in terms of overall survival. (D) Kaplan-Meier curves were generated for the comparisons 
of control (ctr)- Bevacizumab- UniPR1331- and combination of Bevacizumab plus UniPR1331 in terms of overall survival (E) Statistical 
analysis: comparison of Kaplan Meier curves for UniPR1331 alone or in combination with Bevacizumab. n=10.
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Figure 7: Identification of UniPR1331-deregulated miRNAs influencing the “cancer stem cell-regulated angiogenesis” 
in glioblastoma. (A) Volcano plot representation for the global trend of UniPR1331-deregulated miRNAs. The green points represent 
down-regulated miRNAs that have validated targets in GO:0016525 term (negative regulation of angiogenesis); the red points represent up-
regulated miRNAs that have validated targets in GO:0045766 ontology (positive regulation of angiogenesis), according miRWalk analysis. 
(B and C) Relative expression levels (log2[RQ]) of UniPR1331-induced and UniPR1331-reduced miRNAs with experimentally proven 
targeted genes, respectively. (D) Venn diagram shows the numbers of UniPR1331-deregulated miRNAs with validated targets influencing 
the angiogenesis reduction, the glioblastoma disease and their overlaps. (E) Cytoscape 3.4.0 software graphical visualization of miRNA-
target interactions. The colors of each gene node indicate the annotated function of the gene.
Oncotarget24356www.oncotarget.com
cells [22, 27]. Considering that the Eph/ephrin system also 
regulates angiogenesis [10], antagonists of this system 
may elicit beneficial effects in the treatment of several 
cancer types including GBM. Different antibodies or 
recombinant proteins targeting Eph/ephrin system have 
been already used to exploit this cellular system in the 
search for novel cancer therapies. Amongst the available 
therapeutic options, the recombinant EphB4-HSA fusion 
protein [28], the anti-EphA2 monoclonal antibody DS-
8895 (NCT02004717, NCT02252211), the antibody-
drug conjugated PF-06647263 (a humanized monoclonal 
antibody against Ephrin-A4 linked to calicheamicin 
(NCT02078752)) and KB004, [29], are under clinical I 
or II studies for oncological therapies. These tools are 
capable of blocking both forward and reverse signaling; 
however their high specificity towards ephrin-Bs, EphA2 
and EphA3 respectively, represents a potential weakness. 
In fact, signaling mediated by other Eph-ephrin pairs can 
lead to the activation of survival pathways overcoming 
the inhibition of the selected target. Kinase inhibitors 
(dasatinib, Jl-101, XL647) targeting the intracellular 
kinase domain of the Eph receptors are available but 
compared to other agents their use is hampered by limited 
efficacy considering that: 1 they are unable to prevent 
activation of reverse signal generated in the ephrin-
expressing cells, 2. they suffer limited selectivity with 
insurgence of side effects associated to inhibition of other 
kinases (i.e., EGFR, VEGFR, SRC, KIT) [30] and 3. 
they could suffer a difficult access to the target which is 
localized in the cytosol of cancer cells. In this context, 
small molecules targeting Eph/ephrin interaction, such 
as UniPR1331, represent an alternative way to current 
therapeutic approaches based on recombinant proteins 
and kinase inhibitors, as they directly target the interaction 
amongst all the Ephs and ephrins blocking both the reverse 
and forward signaling [12].
Amongst all these targeting agents, the ephrin-B2 
blocking scFv antibody fragment (B11) and the 
radiolabelled lutetium-177 monoclonal antibody IIIA4 
were tested in animal models of GBM. The first strongly 
suppressed tumor growth of highly expressing ephrin-B2 
GSCs orthotopically implanted in mice [11], the latter 
induced a dose-dependent tumor regression of U251MG 
and BAH1 cells subcutaneously xenografted mice [8]. 
Both the treatment showed no evident toxicity.
In this study, we tested for the first time the activity 
of a small molecule (UniPR1331) targeting protein-protein 
interaction which synthesis, chemical characterization 
and preliminary pharmacological investigations at an in 
vitro level were recently published [16]. To the best of our 
knowledge, UniPR1331 is the only orally bio-available 
small molecule that can be regarded as a genuine Eph/
ephrin antagonist, as other small molecules reported to 
block Eph receptors (i.e. 2, 5-dimethyl-pyrrol-1-yl-benzoic 
acid, Rhyncophylline, Protocatechuic acid, Pyrogallol, 
Urolithin D, Epigallocatechin-3, 5-digallate) were recently 
demonstrated to be PAINS, compounds endowed with 
high reactivity and being able to unspecifically react with 
many biological targets [12, 31, 32]. UniPR1331 showed 
good tolerability since only a reduced platelet count, 
which was probably connected to the interference with 
hematopoietic stem/progenitor cells [33], was revealed 
in accordance with previous studies [8, 11]. However, 
future studies should be taken in account to evaluate 
reproductive/developmental toxicity since the Eph/ephrin 
system plays a primary role in embryo development [5].
UniPR1331 dramatically reduced GBM growth 
in two distinct xenograft models (based on U87MG 
and U251MG cells), leading to a significant increase of 
TTP. Biochemical and histological analysis indicated 
that the inhibition of GBM growth was due to a marked 
reduction of blood vessel formation, inhibition of VM and 
activation of apoptosis. In the same models, Bevacizumab 
showed similar efficacy blocking angiogenesis but 
it did not significantly modify cell proliferation or 
apoptosis. Notably, Bevacizumab did not lead to a full de-
vascularization of the tumor as numerous medium-sized 
vessels were still present in the tumor parenchyma at the 
end of the treatment. These vessels were characterized by 
the presence of several GBM cells in the vascular wall 
where they replaced endothelial cells consistent with a 
VM process. The resulting palisade structures, formed by 
a majority of GBM cells, gave origin to numerous vascular 
lacunae, which being dispersed in the tumor parenchyma, 
may supply oxygen and nutrients to tumor cells far 
from the main vessel. VM was previously described as 
a survival mechanism adopted by the tumor tissues [34]. 
During VM, cancer stem-like cells [35] acquire the ability 
to form vessel-like networks mimicking the physiological 
vasculature. In conditions of hypoxia, due to impairment 
in angiogenesis, VM developed as a possible strategy to 
ensure blood supply [36] to cancer cells [37, 38]. Among 
the wide array of signaling systems implicated in VM, the 
Eph receptors have been proposed as novel and relevant 
players. The involvement of the Eph/ephrin system in VM 
has been recently proposed [39, 40] with their aberrant 
expression on GBM cells linked to perivascular invasion 
and vascular co-option [11, 22].
Consistent with this view, combination of 
UniPR1331 with Bevacizumab reduced angiogenesis and 
vasculomimicry leading to large avascular tumor areas 
in U87MG tumors. A fibrotic reaction was also observed 
with the use of UniPR1331, alone or in combination, 
suggesting that its effect modified the structure of the 
tumor parenchyma with areas featured by the lack of 
tumor cells. Since GBM is highly heterogeneous, we 
evaluated whether the activity of UniPR1331 alone or in 
combination could be observed in other GBM models. 
To this end, in addition to U87MG, U251 and TPC8 cells 
were used to generate heterotypic and orthotopic xenograft 
models. Consistent results were obtained in all the tumor 
models, with the combination able to improve the efficacy 
Oncotarget24357www.oncotarget.com
of Bevacizumab. In particular, a significant increase of 
DFS and OS was found when patient-derived glioblastoma 
propagating/undifferentiated/stem cells, TPC8, were 
injected in the brain of nude mice.
TPC8 cells were also used to identify molecular 
pathways that might be affected by use of UniPR1331 
following the significant changes in miRNA expression. 
MiRNAs are small non-coding RNA molecules that 
act by base pairing to complementary regions of their 
mRNA targets, leading to mRNA degradation and/or 
inhibition of protein translation [41]. Remarkably, all 
but one of these miRNAs also targeted genes involved in 
glioblastoma pathogenesis, suggesting a further potential 
molecular explanation of the combined anti-angiogenic 
and anticancer activity of UniPR1331 observed in in vivo 
models.
As observed in Figure 7, 12 miRNAs were up-
regulated by UniPR1331 administration resulting in the 
reduction of a series of gene products including VEGF-A 
(miR-329, miR-263 and mir-34b), WNT5A (miR-
183, miR-487b), Twist1 (miR-183 and miR-329) and 
ANGPT4. Besides the well-known activity of VEGF-A 
on angiogenesis, Wnt5A signaling is emerging as a 
major mediator in cancer progression, regulating cancer 
cell invasion, metastasis and metabolism [42]. Twist1 
upregulation or activation is involved in EMT, metastasis, 
angiogenesis, and is responsible for the “stemness” of 
cancer cells and the generation of drug resistance, gaining 
significance in cancer therapeutics [43]. Angiopoietin-4 is 
involved in glioblastoma progression by enhancing tumor 
angiogenesis and cell viability [44]. Despite reports that 
miR-26b inhibited the VM which processes is regulated 
by EphA2 [45] we have found no relevant difference 
in our experiments. Taken together our data indicate a 
complex network of interactions, where each mRNA can 
be regulated by multiple miRNAs and at one time, each 
miRNA can potentially target multiple genes involved in 
many facets of cancer progression. In this context, our 
work might not represent an exhaustive study investigating 
the functional activity of certain UniPR1331-deregulated 
miRNAs, but aims at providing further evidences that 
UniPR1331 inhibits GBM, by modulating different facets 
of cancer progression.
MATERIALS AND METHODS
Cell lines and cell cultures
All the materials for tissue culture were purchased 
from Euroclone. Human glioma cell lines U251MG and 
U87MG were originally obtained from American Type 
Culture Collection (ATCC, Rockville, MD). Luciferase 
transfected U87MG cells were kindly provided by Jari E. 
Heikkila, Department of Biochemistry and Pharmacy, Abo 
Akademi University, Turku, Finland. Cells were cultured 
at 37°C in 5% CO2 and were maintained as suggested. 
Patient-derived tumor-propagating cells (TPC8) were 
kindly provided by prof. A. Vescovi (Università Bicocca, 
Milano) and Dr L. Balconi (Stemgen, Milano) [22]. To 
confirm their stem-like cell nature immuno-fluorescence 
by confocal analyses and FACS determination were 
performed using Sox2, Nestin, CD44, oct3/4 and GFAP. 
TPC8 were cultured in serum-free DMEM/F-12 (Life 
Technologies) supplemented with EGF/basic FGF. 
hBMVEC (human brain microvascular endothelial 
cells) were kindly provided by Philip M. Cummins, 
School of Biotechnology, Dublin City University, 
Ireland. The endothelial cell line was routinely grown in 
complete endothelial cell medium (EGM™-Plus, Lonza 
Biologics, Slough, UK) containing heparin (0.75 U/ml), 
hydrocortisone (1 μg/ml), recombinant human epidermal 
growth factor (5 ng/ml), EndoGRO-LS Supplement (0.2%) 
and antibiotics. HUVEC (Life Technologies, Waltham, 
MA, USA) were maintained in MEM 200 supplemented 
with 1% penicillin-streptomycin solution, 1% fungizone 
solution, 2% low serum growth supplement and 10% 
FBS. To minimize the risk of working with misidentified 
and/or contaminated cell lines, the cells used in studies 
reported here were stocked at very low passages after 
initial receipt from the vendor to reduce the possibility of 
contaminated cell line stocks and used at < 20 subcultures. 
Periodically, DNA profiling by GenePrint® 10 System 
(Promega Corporation, Madison, WI, USA) was carried 
out to authenticate cell cultures.
Chick-embryo chorioallantoic membrane (CAM) 
assay
The assay was performed as described [46]. 
Briefly, a window was opened in the eggshell of three-
day-old fertilized chicken eggs. At day 11, alginate plugs 
containing VEGF-165 (4.5 pmoles/embryo) in the absence 
or in the presence of the compound (20 pmoles/embryo) 
were placed on the CAMs (8 embryos per group). At day 
14, newly formed blood microvessels converging toward 
the implant were counted.
Anatomo-pathological analysis
Anatomo-pathological analysis were performed 
on 10 male mice treated with UniPR1331 30 mg/kg os. 
Kidneys, spleen, thymus, testicles, accessory sexual 
glands, stomach, segments of duodenum and jejunum, 
heart, lungs and brain were collected from each mouse at 
the end of experimentation and samples were immediately 
fixed in 10% neutral buffered formalin. After paraffin 
embedding, 4-5 μm thick sections, were obtained with 
microtome (Leica), stained with Hematoxylin and Eosin 
(H&E) and Periodic acid-Schiff (PAS). Histological slides 
were examined with Nikon Eclipse E800 microscope 
(Nikon Corporation, Japan) using Nikon PLAN APO 
lenses. Sections were photographed at 4x, 10x, 20x and 
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40x (Nikon PLAN APO lenses) with Camera DIGITAL 
SIGHT DS-Fi1 (Nikon Corporation, made in Japan); 
pictures were acquired with DS Camera Control Unit DS-
L2 (Nikon Corporation, Japan) and stored in USB device. 
Histological lesions were graded and classified based on 
the extension/distribution (focal, multifocal and diffuse) 
and severity (scant, mild, moderate, severe).
Pharmacokinetic studies
UniPR1331 was suspended in 0.5% methylcellulose 
(10/90 v/v) and orally administered as a single gavage 
at 30 mg/kg to male mice. Each group consisted of at 
least three mice. Blood samples were collected via tail 
puncture at different time-points. Whole blood samples 
were centrifuged at 5000 rpm for 10 min, and the resulting 
plasma samples were stored at 20° C pending analysis. 
UniPR1331 was dosed in mouse plasma by HPLC-ESI-
MS/MS using a Thermo Accela UHPLC gradient system 
coupled to a Thermo TSQ Quantum Access Max triple 
quadrupole mass spectrometer (Thermo Italia, Milan, 
Italy) equipped with a heated electrospray ionization 
(H-ESI) ion source. For assessing UniPR1331 CNS 
penetration mice brains were removed and homogenized 
(20% (w/v), wet tissue) in PBS buffer (pH 7.4). The 
compound was quantified using the same approach 
described for blood analysis, but reducing the number 
of time points to 5. Xcalibur 2.1 software (Thermo 
Italia, Milan, Italy) was used for sample injection, peaks 
integration, and plasma level quantification.
In vivo GBM models: xenograft model
Female CD1-nu/nu mice, at 6 weeks of age, 
were purchased from Charles River (Milan, Italy) and 
maintained under EC guidelines (2010/63/UE and DL 
26/2014 for the use of laboratory animals). All mice 
received subcutaneous flank injections of 1 x 106 U87MG 
and U251MG. Tumor growth was assessed bi-weekly by 
measuring tumor diameters with a Vernier caliper. Tumor 
weight was calculated according to the formula: TW (mg) 
= tumor volume (mm3) = d2 x D/2, where d and D are the 
shortest and longest diameters, respectively. The effects 
of the treatments were examined as previously described 
[48]. At about 20 days after the tumor injection, mice 
with tumor volumes of 200 mm3 were randomized to 
receive vehicle, Bevacizumab (4 mg/kg iv every 4 days), 
or UniPR1331 (30 mg/kg po qd), or combinations of 
Bevacizumab with UniPR1331. The duration of treatments 
was 30 days when control/untreated tumors reached 
critical volumes for animal welfare laws. Treated and 
untreated animals were, therefore, sacrificed by carbon 
dioxide inhalation and tumors were subsequently removed 
surgically at the same time. This was necessary for the 
biochemical and histological analyses. A part of the tumor 
was, indeed, directly frozen in liquid nitrogen for protein 
analysis and the other part was fixed in paraformaldehyde 
overnight for immunohistochemical analyses. The 
following parameters were used to quantify the antitumor 
effects of different treatments as previously described [47]: 
(1) tumor volume, measured throughout the experiment, 
(2) tumor weight, measured at the end of experiment; 
(3) tumor progression (TP) defined as an increase of 
100% of tumor volume (named also doubling time) with 
respect to baseline in preclinical model in agreement with 
Reynold et al [48]. The use of TTP over tumor growth 
curves was chosen to reflect the pharmacological efficacy 
assessment in humans and to reduce the variability given 
by volumetric measures due to differences of engraftment 
of the tumor cells as well as the individual variability [47]. 
Combination index of dual administrations was calculated 
accordingly to Bruzzese et al [49].
Orthotopic intra-brain model
Nude mice were inoculated intra-cerebrally as 
follows [50]. Animals were anesthetized with 100 mg/
kg ketamine, 15 mg/kg xylazine. The surgical zone was 
swabbed with Betadine solution, the eyes coated with 
Lacri-lube. The head was fixed in a stereotactic frame 
(mouse stereotaxic instrument, Stoelting Europe, Dublin, 
Ireland) and a midline scalp incision was made. A small 
hole was made at 1.0 mm anterior and 2 mm lateral to the 
exposed bregma. A sterile 5-μL Hamilton syringe with a 
26 gauge needle was inserted to a depth of 3.0 mm from 
the skull surface and withdrawn by 0.5 mm to inject 3 
× 103 U87MG or TPC8 cells in a volume of 3 μL. The 
injection rate was set to 1 μL/min. After the implantation 
of the tumor cells, the needle was left in place for 5 
min to prevent reflux. The needle was then completely 
withdrawn from the brain over the course of 4 min and the 
skin was sutured. Treatments were started 5 days after cell 
injection when no luciferase activity was intracranially 
detectable. At this time, animals were randomized to 
receive vehicle, Bevacizumab (4 mg/kg iv every 4 days), 
or UniPR1331 (30 mg/kg po qd), or combinations of 
Bevacizumab with UniPR1331. Weekly, animals were 
tested for bioluminescence assay. The time in which a 
visible bioluminescence lesion defined the disease-free 
survival (DFS). Repeated bioluminescence assays were 
planned in order to have also data on tumor progression. 
Bioluminescence imaging (BLI) was performed by using 
the Alliance Mini HD6 (UVItec Limited, Cambridge, 
United Kingdom) after injection ip with 150 μg/g 
D-luciferin (Synchem UG & Co. Altenburg, Germany) in 
pre-anesthetized animals. Duration of treatments was of 
30 days at the end of which a period of follow-up was 
planned. Mice were euthanized when they displayed 
neurological signs (e.g., altered gait, tremors/seizures, 
lethargy) or weight loss of 20% or greater of pre-surgical 
weight. Follow-up provide us data on overall survival 
defined as the time (days) in which the animal into account 
showed the distress signs considered (euthanized time). 
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Brains were collected, fixed with 4% paraformaldehyde 
and paraffin embedded.
Histological analysis
Immunohistochemical evaluation were performed 
for EphA2 and p-Tyr EphA2 in U87MG xenografts. 
Indirect immunoperoxidase staining of tumor xenografts 
samples was performed on paraffin-embedded tissue 
sections (4 μm) following standard conditions. The 
evaluations were recorded as the percentage of positively 
stained tumor cells in each of three intensity categories. 
A consensus judgment as indicated in our previous report 
[51] was adopted as to the proper immunohistochemical 
score of the tumors based on the strength of antigen 
expression: negative (score 0), weak staining score 1), 
moderated staining (score 2), or strong staining (score 
3). In each category, the percentage of positively stained 
tumor cells was assessed by scoring at least 1000 adjacent 
cells in the area with the highest density of antigen-
positive cells. Slides were analyzed separately by CF, GLG 
and RS. Cytoplasmic/membrane staining intensity was 
graded as follow: 0= negative; 1= less of 10% of positive 
cells; 2= positive cells in a range of 10-50% and 3= more 
than 50% positive cells. Staining Index (SI), an indicator 
of overall expression levels, ranged between 0 and 9 
with an SI ≤ 4 indicating a low expression. Ki67 labeling 
index was determined by counting 500 cells at 100X and 
determining the percentage of cells staining positively 
for Ki67. Apoptosis was determined by using the TACS 
TdT in situ TACS Blue Label kit (code 4811-30-K; R&D 
Systems, Inc. Minneapolis, MN). Apoptosis was measured 
as the percentage of tunnel positive cells measured on five 
random fields (400 X). Tumor microvessels were counted 
at ×400 in five arbitrarily selected fields and the data 
were presented as number of CD31+ microvessels/×100 
microscopic field for each group. The presence of red cells 
in tumor tissue and in blood vessels as well as the presence 
of micro-thrombi and bleeding zones was demonstrated 
by Martius yellow-brilliant crystal scarlet blue technique.
MiRNA isolation and real-time quantitative 
PCR analysis
Total RNA, miRNAs enriched, was extracted 
from the glioblastoma cell lines at baseline and after 
treatment with UniPR1331 compound, using the AllPrep 
DNA/RNA/miRNA Universal kit (Qiagen, Germany) 
according to the manufacturer’s instructions. RNA 
quantification and purity was measured with Qubit 
Fluorometer v3.0 (Thermo Scientific). Seven-hundred 
ng of RNA was subjected to retro-transcription (RT) by 
using the TaqMan® Micro-RNA Reverse Transcription 
kit (Thermo Fisher Scientific, CA, USA) and analyzed 
for miRNAs’ expression levels with the TaqMan® 
human microRNA array A and array B v3.0 (Thermo 
Fisher Scientific). The two arrays consist in two 384-
well microfluidic cards containing primers and probes 
for 754 different human miRNAs in addition to 3 small 
nucleolar RNAs that function as endogenous controls 
for data normalization. Six μl of each RT reaction was 
combined with 450 μ of TaqMan® Universal PCR Master 
Mix, No AmpErase® UNG, 2✕ (Thermo Fisher Scientific) 
and 444 μl of nuclease-free water. One hundred μl of the 
sample/master mix for each multiplex pool were loaded 
into fill reservoirs of the microfluidic cards; the array 
was then centrifuged and mechanically sealed with the 
Applied Biosystems sealer device. Quantitative PCR was 
carried out on an ViiA-7 system thermo-cycler (Thermo 
Fisher Scientific) using the manufacturer’s recommended 
cycling conditions. Data analysis was performed by using 
the SDS software version 2.3 (Thermo Fisher Scientific) 
and the baseline and threshold were automatically set. The 
average levels of miRNAs expression in all samples were 
normalized relative to the average amounts of U6 small 
nuclear RNA (U6 snRNA). The ΔΔCt comparative method 
was applied to measure the miRNAs that are differentially 
expressed between the UniPR1331-treated and untreated 
cells. We considered Relative Quantification values 
RQ ≥2 or RQ≤ 0.5 as up- and down-regulation cut-off, 
respectively.
Computational analysis
MiRNAs potentially influencing the angiogenesis 
reduction were identified by selecting validated and 
predicted miRNAs targeting angiogenesis-related genes 
through the miRWalk 2.0 bioinformatic tool [52]. The 
miRWalk Validate Module was first queried to identify 
UniPR1331-induced miRNAs having experimentally 
verified targets genes in “positive regulation of 
angiogenesis” Gene Ontology term (GO:0045766) 
database and UniPR1331-reduced miRNAs with targets in 
“negative regulation of angiogenesis” term (GO:0016525) 
database and then to select miRNAs also involved in 
glioblastoma disease, according to the Disease Ontology 
DOID:3068. The experimentally validated interaction 
between UniPR1331-deregulated miRNAs and genes 
involved in GO:0045766, GO:0016525 and/or DOID:3068 
ontologies were included in Cytoscape 3.4 [53] tools 
to provide a graphical representation of miRNAs-
targets interactions. For predictive enrichment analysis 
of UniPR1331-deregulated miRNAs in angiogenesis 
functional GO:0045766 or GO:0016525 pathways, 
miRNAs predicted with a p-value <0.01 to bind their 
targets were considered potentially involved in reduction 
of angiogenesis and the relative genes as highly probable 
targets transcript. The Venny2.0 tool was used to draw the 
Venn diagram [54].
MiRWalk algorithm
The Prediction Module of the miRWalk algorithm 
is a comparative platforms that predicts miRNA binding 
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sites based on a comparison of data from 13 established 
miRNA-target prediction tools: DIANA-microTv4.0, 
DIANA-microT-CDS, miRanda-rel2010, mirBridge, 
miRDB4.0, miRmap, miRNAMap, doRiNA i.e., PicTar2, 
PITA, RNA22v2, RNAhybrid2.1, and Targetscan6.2. The 
miRWalk Validated Module documents experimentally 
verified miRNA-target interaction information collected 
via an automated text-mining search and data from 
existing resources (miRTarBase, PhenomiR, miR2Disease 
and HMDD) offer such information. MiRNAs potentially 
influencing the angiogenesis reduction were identified 
by selecting validated and predicted miRNAs targeting 
angiogenesis-related genes through miRWalk Predicted 
Module and miRWalk Validate Module. For the enrichment 
of miRNAs in angiogenesis functional pathways, the 
miRWalk Prediction Module was used against Gene 
Ontology Biological Process “positive regulation of 
angiogenesis” term (GO:0045766 for UniPR1331-induced 
miRNAs and “negative regulation of angiogenesis” term 
(GO:0016525) for UniPR1331-repressed miRNAs, that 
include respectively 78 and 51 genes. The list of miRNAs 
predicted by miRWalk algorithm to interact with at least 
one of genes associated to GO:0045766 and GO:0016525 
ontologies was compared to the list of UniPR1331-induced 
miRNAs or UniPR1331-repressed miRNAs, respectively. 
The resulting UniPR1331-deregulated miRNAs targeting 
GO:0045766 or GO:0016525 related genes and having 
the interaction p-value <0.01 were considered potentially 
involved in reduction of angiogenesis and the relative 
genes as highly probable targets. The miRWalk Validate 
Module was queried to identify UniPR1331-deregulated 
miRNAs having experimentally verified targets genes in 
GO:0045766 or GO:0016525 ontologies and then to select 
miRNAs also involved in glioblastoma disease, according 
to the Disease Ontology DOID:3068.
Statistical details
Continuous variables were summarized as mean and 
standard deviation (SEM) or as median and 95% CI. For 
continuous variables not normally distributed, statistical 
comparisons between control and treated groups were 
established by carrying out the Kruskal-Wallis Tests and 
Dwass-Steel-Chritchlow-Fligner method. For continuous 
variables normally distributed, statistical comparisons 
between control and treated groups were established 
by carrying out one- or two-way ANOVA test (further 
details in the panel’s legend). Significant differentially 
expressed miRNAs were detected through Student paired 
t-test. TTP was analyzed by Kaplan-Meier curves and 
Gehan’s generalized Wilcoxon test. The use of Kaplan 
Meier Curves allow investigators to study a wide range 
of planned pre-specific events or endpoints such as 
death, disappearance or progression of a tumor also in 
preclinical settings. When more than two survival curves 
were compared the Log rank test for trend was used. 
This tests the probability that there is a trend in survival 
scores across the groups. All tests were two-sided and 
were determined by Monte Carlo significance. P values 
<0.05 were considered statistically significant. MedCalc 
was used as a complete statistical program. We analyzed 
Kaplan Meier curves [48] in term of hazard ratios (HR), 
an expression of the hazard or chance of events occurring 
in the treatment arm as a ratio of the hazard of the events 
occurring in the control arm.
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